Literature DB >> 7531511

Nitric oxide in essential and renal hypertension.

R MacAllister1, P Vallance.   

Abstract

L-Arginine-derived nitric oxide (NO) maintains the systemic and renal vasculature in a state of active vasodilation. Inhibition of NO synthesis increases renal vascular tone, reducing RBF and GFR. Similar effects reproduced in other vascular beds result in systemic hypertension. In addition, NO modulates natriuresis by a direct effect on renal tubular function. Abnormalities of the L-arginine:NO pathway occur in experimental hypertension and renal disease and could contribute to alterations in vascular tone; similar abnormalities are seen in essential hypertension in humans. In dialysis-dependent renal failure, the accumulation of endogenous compounds that inhibit NO synthase could exacerbate renal hypertension by inhibiting vascular and renal tubular NO synthesis and might provoke atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531511     DOI: 10.1681/ASN.V541057

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

1.  Exogenous L-arginine does not affect angiotensin II-induced renal vasoconstriction in man.

Authors:  M Wolzt; A Ugurluoglu; L Schmetterer; G Dorner; G Zanaschka; C Mensik; H G Eichler
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

2.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.

Authors:  J M Leiper; J Santa Maria; A Chubb; R J MacAllister; I G Charles; G S Whitley; P Vallance
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

3.  Platelet-derived growth factor and fibroblast growth factor differentially regulate interleukin 1beta- and cAMP-induced nitric oxide synthase expression in rat renal mesangial cells.

Authors:  D Kunz; G Walker; W Eberhardt; U K Messmer; A Huwiler; J Pfeilschifter
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

4.  Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.

Authors:  Ivanka Mikulić; József Petrik; Kresimir Galesić; Zeljko Romić; Ivana Cepelak; Monika Zeljko-Tomić
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 5.  Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.

Authors:  Seiji Ueda; Sho-Ichi Yamagishi; Yuriko Matsumoto; Kei Fukami; Seiya Okuda
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

6.  Effect of simvastatin on culturing of kidney cells from pigs in vitro.

Authors:  Guifen Liu; Haichao Lin; Jinlian Fu; Aiguo Wang
Journal:  Mol Biol Rep       Date:  2009-04-03       Impact factor: 2.316

Review 7.  Nitrate tolerance and the links with endothelial dysfunction and oxidative stress.

Authors:  Katherine E Fayers; Michael H Cummings; Kenneth M Shaw; David W Laight
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

8.  Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney.

Authors:  Giovanni Corsetti; Giuseppe D'Antona; Chiara Ruocco; Alessandra Stacchiotti; Claudia Romano; Laura Tedesco; Francesco Dioguardi; Rita Rezzani; Enzo Nisoli
Journal:  Amino Acids       Date:  2014-06-13       Impact factor: 3.520

9.  Effect of high-altitude trekking on blood pressure and on asymmetric dimethylarginine and isoprostane production: Results from a Mount Ararat expedition.

Authors:  Vittore Verratti; Claudio Ferrante; Davide Soranna; Antonella Zambon; Suwas Bhandari; Giustino Orlando; Luigi Brunetti; Gianfranco Parati
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-06       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.